<DOC>
	<DOC>NCT00412152</DOC>
	<brief_summary>The primary objective of this study is to demonstrate that subjects with moderate to severe non-malignant pain taking oxycodone/naloxone prolonged release tablets have improvement in symptoms of constipation compared to subjects taking oxycodone prolonged release tablets alone.</brief_summary>
	<brief_title>Oxycodone-naloxone in Relieving Opioid-related Constipation</brief_title>
	<detailed_description>Patients with a documented history of moderate to severe non-malignant pain that require around the clock opioid therapy will be randomised to an oxycodone or an oxycodone-naloxone treatment arm to assess the safety and efficacy of oxycodone/naloxone prolonged release compared to oxycodone prolonged-release in relieving opioid-related constipation.</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<criteria>Male or female subjects at lest 18 years or older with pain. Subjects must report constipation caused or aggravated by opioids. Females who are pregnant or lactating. Subjects with evidence of significant structural abnormalities of the gastrointestinal (GI) tract (e.g. bowel obstruction, strictures).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>A randomised</keyword>
	<keyword>double blind</keyword>
	<keyword>parallel group</keyword>
	<keyword>multicentre study to demonstrate improvement in symptoms of constipation in subjects with non malignant pain</keyword>
	<keyword>Moderate to severe chronic non-malignant pain</keyword>
</DOC>